The IFN-γ-TOPK-eIF4F-STAT1-PD-L1/IDO1 axis as a crucial regulator of the tumor immunometabolic microenvironment and provide novel insights into the combination of targeted therapy and immunotherapy for GC treatment. This evidence concerns the gene CD274 and neoplasm.